Dynavax Technologies (NASDAQ:DVAX) and Diffusion Pharmaceuticals (NASDAQ:DFFN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Valuation & Earnings
This table compares Dynavax Technologies and Diffusion Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dynavax Technologies||$330,000.00||2,352.99||-$95.15 million||($1.73)||-7.17|
|Diffusion Pharmaceuticals||N/A||N/A||-$1.36 million||($1.14)||-0.38|
Diffusion Pharmaceuticals has lower revenue, but higher earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Diffusion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
82.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 7.6% of Diffusion Pharmaceuticals shares are held by institutional investors. 3.5% of Dynavax Technologies shares are held by company insiders. Comparatively, 5.8% of Diffusion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Dynavax Technologies and Diffusion Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dynavax Technologies currently has a consensus price target of $27.50, indicating a potential upside of 121.77%. Diffusion Pharmaceuticals has a consensus price target of $1.25, indicating a potential upside of 189.55%. Given Diffusion Pharmaceuticals’ higher possible upside, analysts plainly believe Diffusion Pharmaceuticals is more favorable than Dynavax Technologies.
Volatility & Risk
Dynavax Technologies has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Diffusion Pharmaceuticals has a beta of -1.75, suggesting that its share price is 275% less volatile than the S&P 500.
This table compares Dynavax Technologies and Diffusion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Diffusion Pharmaceuticals beats Dynavax Technologies on 8 of the 12 factors compared between the two stocks.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company’s lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Receive News & Ratings for Dynavax Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dynavax Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.